Encompass Health (NYSE:EHC) Updates FY22 Earnings Guidance

Encompass Health (NYSE:EHCGet Rating) updated its FY22 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $3.83-4.19 for the period, compared to the Thomson Reuters consensus estimate of $4.11. The company issued revenue guidance of $5.38-5.50 billion, compared to the consensus revenue estimate of $5.45 billion.

EHC has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Encompass Health from $95.00 to $80.00 in a research note on Thursday, January 20th. Zacks Investment Research upgraded shares of Encompass Health from a sell rating to a hold rating and set a $76.00 price objective for the company in a report on Monday, April 11th. Truist Financial raised their price objective on shares of Encompass Health from $78.00 to $85.00 in a research report on Thursday, April 7th. Raymond James dropped their target price on shares of Encompass Health from $90.00 to $80.00 and set a strong-buy rating for the company in a research report on Monday, February 7th. Finally, TheStreet raised shares of Encompass Health from a c+ rating to a b- rating in a research note on Tuesday, March 15th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $83.89.

Encompass Health stock traded up $0.47 during trading hours on Friday, hitting $68.83. 1,361,665 shares of the stock traded hands, compared to its average volume of 636,669. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.23 and a quick ratio of 1.23. The firm’s 50 day moving average price is $69.30 and its 200-day moving average price is $66.00. The stock has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 2.23 and a beta of 0.99. Encompass Health has a 1 year low of $56.31 and a 1 year high of $88.58.

Encompass Health (NYSE:EHCGet Rating) last announced its earnings results on Wednesday, April 27th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Encompass Health had a return on equity of 18.36% and a net margin of 7.51%. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the prior year, the firm earned $1.05 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. Research analysts forecast that Encompass Health will post 4.11 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, April 18th. Stockholders of record on Friday, April 1st were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Thursday, March 31st. This represents a $1.12 annualized dividend and a dividend yield of 1.63%. Encompass Health’s dividend payout ratio is currently 28.64%.

A number of institutional investors have recently bought and sold shares of EHC. BlackRock Inc. increased its position in shares of Encompass Health by 1.4% during the fourth quarter. BlackRock Inc. now owns 10,643,463 shares of the company’s stock worth $694,594,000 after purchasing an additional 145,130 shares in the last quarter. Morgan Stanley boosted its stake in shares of Encompass Health by 27.5% during the 2nd quarter. Morgan Stanley now owns 670,104 shares of the company’s stock worth $52,288,000 after acquiring an additional 144,463 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Encompass Health by 27.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 416,059 shares of the company’s stock worth $27,153,000 after purchasing an additional 89,130 shares during the last quarter. Parametric Portfolio Associates LLC raised its holdings in Encompass Health by 4.7% in the 4th quarter. Parametric Portfolio Associates LLC now owns 266,982 shares of the company’s stock valued at $17,423,000 after acquiring an additional 12,031 shares during the last quarter. Finally, Comerica Bank raised its holdings in Encompass Health by 5.2% in the 4th quarter. Comerica Bank now owns 164,044 shares of the company’s stock valued at $10,208,000 after acquiring an additional 8,147 shares during the last quarter. Institutional investors own 92.35% of the company’s stock.

Encompass Health Company Profile (Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

See Also

Earnings History and Estimates for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.